NEPHROLOGY DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Nephrology Drugs Market, By Route of Administration (Oral, Parenteral, Others), By Drug Class (ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jun 2024
Code : CMI7083
Pages :179
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Nephrology Drugs Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Growing Geriatric Population

Rising geriatric population worldwide, who are more susceptible to developing kidney diseases, can drive the market growth. Older adults often have coexisting conditions such as hypertension, cardiovascular diseases, and diabetes which further elevate the risk. Moreover, aging physiology makes the kidneys less efficient over time. According to the data from United Nations, there were over 727 million people aged 65 years and above globally in 2020, which accounted for nearly 9% of the world's population. This geriatric demographic is expected to double to 1.5 billion by 2050. Aged individuals require more vigilant nephrology care and long term pharmacotherapy using multiple drugs. With rising life expectancy, there will be increase in consumption of nephrology medications by elderly population. Expanding aging demographics coupled with associated complex medical conditions can drive the market growth.

Key Players Insights